Author Correction: Effectiveness of mRNA COVID-19 vaccine booster doses against Omicron severe outcomes
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
Author Correction: Effectiveness of mRNA COVID-19 vaccine booster doses against Omicron severe outcomes ; volume:15 ; number:1 ; day:20 ; month:12 ; year:2024 ; pages:1 ; date:12.2024
Nature Communications ; 15, Heft 1 (20.12.2024), 1, 12.2024
- Klassifikation
-
Recht
- Urheber
-
Grewal, Ramandip
Nguyen, Lena
Buchan, Sarah A.
Wilson, Sarah E.
Nasreen, Sharifa
Austin, Peter C.
Brown, Kevin A.
Fell, Deshayne B.
Gubbay, Jonathan B.
Schwartz, Kevin L.
Tadrous, Mina
Wilson, Kumanan
Kwong, Jeffrey C.
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1038/s41467-024-55350-3
- URN
-
urn:nbn:de:101:1-2503012122038.724358107547
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
- 15.08.2025, 07:30 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Grewal, Ramandip
- Nguyen, Lena
- Buchan, Sarah A.
- Wilson, Sarah E.
- Nasreen, Sharifa
- Austin, Peter C.
- Brown, Kevin A.
- Fell, Deshayne B.
- Gubbay, Jonathan B.
- Schwartz, Kevin L.
- Tadrous, Mina
- Wilson, Kumanan
- Kwong, Jeffrey C.
- SpringerLink (Online service)
Ähnliche Objekte (12)
Effectiveness of mRNA COVID-19 vaccine booster doses against Omicron severe outcomes
Neutralization of Omicron XBB.1 by booster vaccination with BA.4/5 monovalent mRNA vaccine
Heterologous mRNA vaccine booster increases neutralization of SARS-CoV-2 Omicron BA.2 variant
Clinical characteristics and booster vaccine effectiveness of the Omicron variant
Bivalent mRNA vaccine booster induces robust antibody immunity against Omicron lineages BA.2, BA.2.12.1, BA.2.75 and BA.5
A booster dose of Delta × Omicron hybrid mRNA vaccine produced broadly neutralizing antibody against Omicron and other SARS-CoV-2 variants
An Omicron-specific, self-amplifying mRNA booster vaccine for COVID-19: a phase 2/3 randomized trial
Immunogenicity of Comirnaty Omicron XBB.1.5 booster COVID-19 mRNA vaccine in long-term survivors after allogeneic hematopoietic stem cell transplantation
Three-month antibody persistence of a bivalent Omicron-containing booster vaccine against COVID-19
mRNA booster vaccination protects aged mice against the SARS-CoV-2 Omicron variant
Omicron-specific mRNA vaccination alone and as a heterologous booster against SARS-CoV-2
An updated RBD-Fc fusion vaccine booster increases neutralization of SARS-CoV-2 Omicron variants
Effectiveness of mRNA COVID-19 vaccine booster doses against Omicron severe outcomes
Neutralization of Omicron XBB.1 by booster vaccination with BA.4/5 monovalent mRNA vaccine
Heterologous mRNA vaccine booster increases neutralization of SARS-CoV-2 Omicron BA.2 variant
Clinical characteristics and booster vaccine effectiveness of the Omicron variant
Bivalent mRNA vaccine booster induces robust antibody immunity against Omicron lineages BA.2, BA.2.12.1, BA.2.75 and BA.5
A booster dose of Delta × Omicron hybrid mRNA vaccine produced broadly neutralizing antibody against Omicron and other SARS-CoV-2 variants
An Omicron-specific, self-amplifying mRNA booster vaccine for COVID-19: a phase 2/3 randomized trial
Immunogenicity of Comirnaty Omicron XBB.1.5 booster COVID-19 mRNA vaccine in long-term survivors after allogeneic hematopoietic stem cell transplantation
Three-month antibody persistence of a bivalent Omicron-containing booster vaccine against COVID-19
mRNA booster vaccination protects aged mice against the SARS-CoV-2 Omicron variant
Omicron-specific mRNA vaccination alone and as a heterologous booster against SARS-CoV-2
An updated RBD-Fc fusion vaccine booster increases neutralization of SARS-CoV-2 Omicron variants
Effectiveness of mRNA COVID-19 vaccine booster doses against Omicron severe outcomes
Neutralization of Omicron XBB.1 by booster vaccination with BA.4/5 monovalent mRNA vaccine
Heterologous mRNA vaccine booster increases neutralization of SARS-CoV-2 Omicron BA.2 variant
Clinical characteristics and booster vaccine effectiveness of the Omicron variant
Bivalent mRNA vaccine booster induces robust antibody immunity against Omicron lineages BA.2, BA.2.12.1, BA.2.75 and BA.5
A booster dose of Delta × Omicron hybrid mRNA vaccine produced broadly neutralizing antibody against Omicron and other SARS-CoV-2 variants
An Omicron-specific, self-amplifying mRNA booster vaccine for COVID-19: a phase 2/3 randomized trial
Immunogenicity of Comirnaty Omicron XBB.1.5 booster COVID-19 mRNA vaccine in long-term survivors after allogeneic hematopoietic stem cell transplantation
Three-month antibody persistence of a bivalent Omicron-containing booster vaccine against COVID-19
mRNA booster vaccination protects aged mice against the SARS-CoV-2 Omicron variant
Omicron-specific mRNA vaccination alone and as a heterologous booster against SARS-CoV-2